Foundation for the Promotion of Health and Biomedical Research of Valencia Region (FISABIO)

If you are the contact person for this centre and you wish to make any changes, please contact us.

SMC participants

Professor of Genetics at the University of Valencia and researcher of the Genomics and Health Area at the Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (Fisabio)

Professor of Genetics at the University of Valencia and researcher at the mixed unit Infection and Public Health FISABIO/Universitat de Valencia

Senior Researcher at FISABIO-Dr. Peset University Hospital

Epidemiologist, researcher in the Health Services and Pharmacoepidemiology Research Area of the Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO) and Director of Gaceta Sanitaria, the scientific journal of the Spanish Society of Public Health and Health Administration (SESPAS)

Contents related to this centre
aeropuerto

The Minister of Health, Carolina Darias, announced today at a press conference that in view of the increase in cases of covid-19 in China following the end of the covid zero policy, Spanish airports are going to require passengers arriving from that country to take a negative test for covid-19 or a complete vaccination schedule. The first flight affected by health control measures will arrive at Adolfo Suárez Madrid-Barajas Airport at 18:00 on 31 December.

China

The end of the zero covid policy in China is leading to an increase in the number of cases and has revived the question of whether the epidemiological situation in China could favour the emergence of new variants of the SARS-CoV-2 coronavirus.

murciélago

A sarbecovirus distantly related to SARS-CoV-2 and found in horseshoe bats in Russia is able to enter human cells using the ACE2 receptor, according to research published in PLOS Pathogens. 

virus viruela del mono

A genomic analysis of monkeypox viruses from patients in the ongoing outbreak reveals that it most likely has a single origin. This 2022 monkeypox virus diverges from those of 2018-2019 in many more genetic variations than expected for Orthopoxviruses, which may represent ongoing accelerated evolution, according to the authors. The study is published in Nature Medicine.

 

Mascarillas

The Minister of Health, Carolina Darias, today announced that face masks will no longer be compulsory indoors after Easter. The measure will come into force on 20 April. It will continue to be compulsory in public transport, health centres and residences, but the final details of the new scenario are not yet known.

test

The Public Health Commission has updated the Covid-19 Surveillance and Control Strategy, which will come into force on Monday 28 March. From then on, as long as indicators of healthcare utilisation are at low risk, diagnostic testing will focus on vulnerable individuals and settings and severe cases. Surveillance will focus on these groups.

covidauto

In recent days, several countries have modified the quarantine times for close contacts and the isolation of infected people, while others are already considering it. Spain has announced that it will reduce these periods to 7 days, both for people who have tested positive in a test and for close contacts who require quarantine (in the case of our country, unvaccinated people).

Vaccine

The misleading presentation of hospitalization data, ICU admissions or deaths in vaccinated and unvaccinated persons that we are seeing these days in some media and social networks are generating confusion about the effectiveness of these preparations.

PCR

A new variant of the coronavirus causing COVID-19 has been identified in South Africa, with numerous mutations present in other variants, including Delta. Variant B.1.1.529, as it is now called, appears to be spreading rapidly in South Africa. Attached is the rapid reaction of three Spanish researchers with expertise in genomic surveillance.

Fluvoxamina

A clinical trial in Brazil evaluated the effectiveness of a depression drug versus placebo in reducing the risk of hospitalisation for SARS-CoV-2 infection. Administration of 100 mg twice daily for ten days to high-risk outpatients with early diagnosis reduces the need for hospitalisation.